NeoGenomics is trading at $14.75 (10% up) following a strong second-quarter earnings report and upgraded full-year guidance.
- The company reported 11% revenue growth and swung to a profit, significantly exceeding investor expectations.
- Management raised its 2026 revenue and adjusted EBITDA outlook, signaling long-term growth confidence.
- A broader rally in the healthcare sector following positive earnings reports is providing additional tailwinds for the stock.